HVHR's product range covers hemostasis, surgical sealing, anti-adhesion, soft tissue management, and other comprehensive categories. The company has obtained over 50 medical device registration certificates, including two Class III medical devices, with five products recognized as "Innovative Medical Devices" by the National Medical Products Administration or corresponding provincial authorities. Several of the company's products hold unique advantages and leading positions in the domestic market, filling market gaps and enhancing the company's core competitiveness and industry recognition.
The company places great emphasis on research and innovation, having established a comprehensive R&D system and a high-quality R&D team led by Academician Fu Xiaobing, with Dr. Yu Kui as the R&D lead. The team is dedicated to the continuous development and research of biosurgical technologies. To date, the company has obtained nearly 100 patents for core technologies, continuously driving technological innovation and product upgrades, and injecting strong momentum into the company's sustainable development.
HVHR has meticulously cultivated its product channels for many years, now covering over 200 prefecture-level cities in China and serving more than 1,500 hospitals. These include the Chinese People's Liberation Army General Hospital, Southwest Hospital of Army Medical University, The First Affiliated Hospital of Naval Medical University, Eastern Theater Command General Hospital, and the 909th Hospital of the PLA Joint Logistics Support Force. Internationally, its products have entered markets in 19 countries, including Sweden, France, the United States, Chile, Germany, Bahrain, and the United Arab Emirates.
Over the years, HVHR has consistently used new materials to drive medical applications, continuously providing innovative products and comprehensive solutions for the fields of burns, trauma, and wound repair in China, having served hundreds of millions of patients cumulatively. With strong technology, products, and services, HVHR strives to build a premium brand in China's injury and repair industry. In recent years, the company has developed multi-level combat casualty first aid kits and a variety of combat casualty first aid products, demonstrating its commitment to contributing to national defense.
Following this round of financing, HVHR will focus on advancing the construction of its biomedical materials production expansion base, including products such as bio-3D printing inks and biomedical intermediates. This will enhance the large-scale production capacity of high-end medical products while accelerating automated production and intelligent management processes to optimize supply chain efficiency. Additionally, the company will continue to increase R&D investment, register new products such as bacterial cellulose artificial blood vessels and bacterial cellulose beverages, and promote the application of innovative materials in clinical medicine and the broader health industry, providing superior solutions for healthcare professionals and patients.
Future Outlook: Technology + Healthcare + Consumer, Building a New Industrial Ecosystem. Guided by its core philosophy of "Trustworthy Innovation," HVHR is dedicated to becoming a benchmark enterprise that integrates technology, healthcare, and consumer sectors. In the future, the company will continue to explore unmet clinical needs, expand its product matrix, cover broader market scenarios, and contribute to improving the quality of life for patients worldwide.
